Cellyan Biotechnology (HKPD) director CHAN Kam Leung files initial Form 3

Rhea-AI Filing Summary

Cellyan Biotechnology Co., Ltd director CHAN Kam Leung filed an initial Form 3, which is a required insider ownership report when someone becomes a director or other reporting person. This filing lists their insider status with the company but shows no reported transactions or derivative positions.

Key Terms

Form 3, reporting person, derivative securities

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3)"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reporting person regulatory

""reportingPersons": [{"name": "CHAN Kam Leung""

derivative securities financial

""derivativeSummary": []"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 06/12/2026 - 07:01 AM Accepted by SEC EDGAR 06/12/2026 - 07:01 AM Learn about SEC filing dates

FAQ

What does Cellyan Biotechnology (HKPD) report in this Form 3 filing?

The Form 3 identifies CHAN Kam Leung as a director of Cellyan Biotechnology. It serves as an initial insider ownership report and does not list any stock transactions or derivative positions in the summarized data provided.

Who is the reporting person in Cellyan Biotechnology (HKPD) Form 3?

The reporting person is CHAN Kam Leung, listed as a director of Cellyan Biotechnology Co., Ltd. The filing confirms their status as an insider subject to reporting requirements on future share transactions under U.S. securities rules.

Are there any stock transactions disclosed for HKPD in this Form 3?

No stock transactions are disclosed in this Form 3. The transaction summary shows zero buys, zero sells, and no derivative exercises, indicating this is purely an initial insider ownership report without trading activity in the provided data.

Does the Cellyan Biotechnology (HKPD) Form 3 show any derivative securities?

The summarized data shows no derivative securities for CHAN Kam Leung. The derivativeSummary is empty and exercise-related counts are zero, indicating no options, warrants, or other derivatives are reported in this initial Form 3 snapshot.

Why is a Form 3 important for Cellyan Biotechnology (HKPD) investors?

Form 3 establishes who qualifies as an insider at Cellyan Biotechnology. Once filed, that person must report later trades on Forms 4 and 5, giving investors ongoing visibility into insider transactions and changes in ownership stakes over time.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

CHAN Kam Leung

(Last) (First) (Middle)

FLAT C, 35/F, BLOCK 5, FLORA PLAZA

88 PAK WO ROAD, FANLING

(Street)

NEW TERRITORIES 00000

(City) (State) (Zip)

HONG KONG

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Cellyan Biotechnology Co., Ltd [ HKPD ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Kam Leung Chan	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)